Xspray Pharma
32.45 SEK
+0.62 %
Less than 1K followers
XSPRAY
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+0.62 %
+30.32 %
-32.75 %
+5.55 %
-20.30 %
-27.63 %
-36.82 %
-78.23 %
+7.45 %
Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.
Read moreMarket cap
1.35B SEK
Turnover
778.54K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12/2
2026
Annual report '25
6/5
2026
Interim report Q1'26
12/5
2026
General meeting '26
All
Webcasts
Press releases
ShowingAll content types
Interim Report Third Quarter 2025
Delårsrapport tredje kvartalet 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
